Adm. Brett Giroir pushed back on some of the public health recommendations made by his colleague on the White House Coronavirus Task Force, Dr. Anthony Fauci.
Steps like closing bars and wearing masks could have the same impact as widespread economic shutdowns, Admiral Brett Giroir said Sunday.
Email from HHS adviser accusing CDC of ‘undermining President’ offers window into pressure on nation’s public health agency.
President Trump repeatedly hyped an obscure antimalarial drug, hydroxychloroquine, as a potential miracle cure for COVID-19. But there was almost no solid scientific evidence to back that claim, and researchers quickly established that it had no effect on the disease. Despite its unlikely profile as a cure, hydroxychloroquine has received more federal research funding than any other single potential treatment, an Insider investigation has found. Taxpayers have devoted at least $88 million — and likely much more — on research and prescriptions for the drug. "It's been a disaster," Arthur Caplan, the founder of New York University School of Medicine's division of medical ethics, said. "There's too much money … chasing around that drug based on very weak evidence in the literature and a presidential endorsement." Visit Business Insider's homepage for more stories . Most Americans had never heard of hydroxychloroquine — the obscure antimalarial drug discovered in 1945 — until March 19. That's when President Donald Trump, speaking at a Coronavirus Task Force press conference in the White House briefing room with the blustering confidence of an old-time snake-oil salesman, first touted it as a likely miracle cure to defeat COVID-19.
The U.S. Department of Health and Human Services (HHS) said on Tuesday there would be temporary free COVID-19 testing in three cities in Florida, Louisiana and Texas as the U.S. states tackle surging cases and hospitalizations.
WASHINGTON, July 7, 2020 /PRNewswire/ -- The expertise of the U.S. Centers for Disease Control and Prevention (CDC) and all public health agencies is critical to protecting Americans' health during the COVID-19 crisis, said a letter to Health and Human Services Secretary Alex Azar from…
Sen. Elizabeth Warren is raising concerns over an effort to track coronavirus spread that involves tech company Palantir.
The US Department for Health and Human Services (HHS) announced on July 1 that it will be buying up virtually the entire stock of Gilead’s remdesivir drug, which has been found to be effectiv…
The US Department of Health and Human Services (HHS) was able to secure 100 per cent of Gilead Sciences’ projected production of remdesivir for July, and 90 per cent of its production for August and September.
Amid record unemployment, HHS is doling out more than $1 billion in coronavirus contracts that omit price-gouging safeguards. The post The Trump Administration Is Waiving the Public’s Right to Affordable Coronavirus Treatments appeared first on The Intercept .
The US has struck a deal with Gilead Sciences to purchase more than 90% of the global supply of remdesivir. Remdesivir has been shown to help moderately ill patients recover more quickly from COVID-19, and is only of the only treatments that has been found to be as effective. HHS secretary Alex Azar called it an "amazing deal," but it leaves many countries with few options. The treatment, which was previously donated by Gilead, has now been priced at $2,340 per course for developed nations, including the US. Visit Business Insider's homepage for more stories . The US has purchased more than 90% of the world's supply of remdesivir, the only proven treatment for COVID-19, which will leave little for the rest of the world for at least the next three months. Gilead Sciences, the US-based company that makes the drug, agreed to sell more than 500,000 treatment courses to the US until September, which is almost the entire amount it has the ability to produce. Remdesivir, which was originally developed to treat Ebola, has been shown to help moderately ill patients recover more quickly from COVID-19, and was granted temporary FDA approval for that purpose in early May.
That means that the cost of a five-day treatment course in the U.S. and other developed countries will jump to $3,120.
The price for U.S. private insurance companies will be $520 per vial, the drugmaker said, which equates to $3,120 per patient for a treatment course using 6 vials of remdesivir. Gilead has entered into an agreement with the U.S. Department of Health and Human Services (HHS), with the agency and states
Azar also denied that states reopening prematurely was tied to the spike in coronavirus cases and instead blamed "inappropriate individual behavior" that has spread the virus.
HHS ecretary Alex Azar defended Trump's decision to not wear a face covering in public on Sunday, saying the president is tested for the coronavirus on a daily basis so wearing a mask isn't necessary.
- ← précédent
- suivant →